Company Profile · Healthcare

Apeloa Pharmaceutical Co Ltd

000739 · Shenzhen
Country
China
IPO date
May 9, 1997
Employees
6,787
Buffett Score
71/100
Strong
Market capCN¥32.14B
Revenue (TTM)CN¥9.16B
EBITDACN¥1.6B
Profit margin9.28%
ROE12.75%
P/E (TTM)37.49
Forward P/E0
PEG0
EPSCN¥0.74
Dividend yield1.42%
52-week rangeCN¥14.70 – CN¥27.89

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&D and production services CDMO include R&D services, commercial human drug projects, commercial veterinary drug projects and other commercial projects; pharmaceutical business includes anti-infective, cardiovascular, psychotropic, hepatobiliary and anti-tumor categories. The company also provides technology platforms, such as flow chemistry, synthetic biology and biocatalysis, crystallization and particle engineering, peptide, high potency compound, conjugate library service, oligonucleotide synthesis, and preparation and purification; and controlled-release formulation development, taste masking technology, and particle flow simulation. In addition, it exports its products under the Tianliwei, Baishixin, Li'an, Jutai, and other brands. Apeloa Pharmaceutical Co.,Ltd was founded in 1989 and is based in Dongyang, the People's Republic of China.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

No reports on this stock in your language yet.